

Method Developments of Pyridine Pyrimidine and Dioxane Activity of Heterocyclic Compounds

Dr. Ankit Singh Shekhawat

Assistant Professor, Department of Pharmacy

Shri Jagdish Prasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India

Abstract: *The heterocyclic compounds are organic compounds that contain a ring structure containing atoms in addition to carbon, such as sulfur, oxygen or nitrogen, as part of the ring.[1] They may be either simple aromatic rings or non-aromatic rings. Some examples are pyridine (C₅H₅N), pyrimidine (C₄H₄N₂) and dioxin (C₄H₈O₂). Heteroatom's as well as heterocyclic scaffolds are frequently present as the common cores in pharmaceutical natural products. Pyridine and pyrimidine derivatives have received in pharmacological research; these are used in the treatment of myeloid leukemia, breast cancer and idiopathic pulmonary fibrosis. Quantitative assessment of any medication is fundamental contraption in industry. Find that unpleasant material, generally engaging things and moreover last things meet its points of interest and are of required quality. Measure of pharmaceuticals and medication definitions brought into business portion has been stretching out at maddening rate. Couples of medications are open as pharmaceutical unobtrusive components to control illnesses. Frameworks for separating and measure for controlling social event of these synthetic compounds in plans and in living body are significant. Pharmaceutical assessment remembers essential part for legal accreditation of medications and their definitions either by business or by administrative powers. Adaptable nature of issues experienced in pharmaceutical assessment got together with centrality of accomplishing selectivity, speed, cost, straightforwardness, affectability, exactness and precision brings about new strategies for assessment being immediately gotten by pharmaceutical business.*

Keywords: Pyridine, Pyrimidine, Dioxin Activity of Heterocyclic Compounds

REFERENCES

- [1]. "Heterocyclic Chemistry" by Raj K. Banal 5thEdn, New Age International Publisher, ISBN978-81-224-3143-8.
- [2]. Presto, D.; Quaquarelli, E. The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2-Metastatic Breast Cancer: Biological Mechanisms and New Treatments of Cancers 2019, 11, 1242.
- [3]. Sharma, P.; Kauri, S.; Chatham, B.S.; Kauri, R.; Kauri, M.; Kauri, S. Anticancer and antimicrobial potential of entrain 12a from Enterococcus faecium BMC Microbiol. 2021, 21, 39.
- [4]. Wang, S.; Yuan, X.H.; Wang, S.Q.; Zhao, W.; Chen, X.B.; Yuan, B. FDA-approved pyrimidine-fused bicyclic heterocyclic for cancer therapy: Synthesis and clinical application. Eur. J. Med. Chem. 2021, 2141, 13218.
- [5]. Mohi El-Deen, E.M.; Anwar, M.M.; Hasabelnaby, S.M. Synthesis and in vitro cytotoxic evaluation of some novel hexahydroquinoline derivatives containing benzofuran moiety. Res. Chem. Intermed. 2016, 42, 1863–1883.
- [6]. "Heterocyclic Chemistry" 5thEdn. By, K. Mills and G. F. Smith, Wiley International Publications, ISBN: 978-1-4051-3300-5.
- [7]. Bhutan, P.; Joshi, G.; Raja, N.; Bache, N.; Rajang, P.K.; Bhutan, H.; Paul, A.T.; Kumar, R.U.S. FDA Approved Drugs from 2015–June 2020: A Perspective. J. Med. Chem. 2021, 64, 2339–2381.
- [8]. Al-Trane, S.A.; Tarawneh, A.H.; Gadetskaya, A.V.; Sea, E.; Al-Tatami, M.R.; Al-Taw eel, S.A.; El-Abdullah, M.M. Synthesis and cytotoxicity of thin[2,3-b]pyridine derivatives toward sensitive and multidrug-resistant leukemia cells. Catechism Solve. 2021, 68, 458–465.
- [9]. Mohi El-Deen, E.M.; Abd El-Meguid, E.A.; Hasabelnaby, S.; Karamu, E.A.; Nosier, E.S. Synthesis, Docking Studies, and In Vitro Evaluation of Some Novel Thienopyridines and Fused Thienopyridine–Quinolines as Antibacterial Agents and DNA Gyrate Inhibitors. Molecules 2019, 24, 3650.

- [10]. Mekky, A.E.M.; Salad, S.M.H.; Said, A.Y.; Elneairy, M.A.A. Synthesis, cytotoxicity, in-vitro antibacterial screening and in-silicon study of novel thing [2,3-b]pyridines as potential pim-1 inhibitors. Synth Commun. 2020, 50, 2376–2389.
- [11]. Bensalem, N.K.; Wrigley, C.A.; Whitehead, K.A.; van Ransburg, M.; Reemission, J.; Pilkington, L.I.; Barker, D.; Jones, S.; Dempsey Hebert, N.C. Thin [2,3-b]pyridine derivatives are potent anti-platelet drugs, inhibiting platelet activation, aggregation and showing synergy with aspirin. Eur. J. Med. Chem. 2018, 143, 1997–2004.
- [12]. “Heterocyclic Chemistry” (3rd Edition) by Thomas. L. Gilchrist, Prentice Hall Publication, ISBN 978-0-5822-7843-1.
- [13]. Wang, N.Y.; Zoo, W.Q.; Cu, Y.; Ago, C.; Zing, X.X.; Zhang, L.D.; You, X.Y.; Pang, C.T.; Sheng, Y.; Yang, S.Y.; et al. Discovery and structure–activity relationships study of novel thing[2,3-b]pyridine analogues as hepatitis C virus inhibitors. Borg. Med. Chem. Left. 2014, 24, 1581–1588.